阿立哌唑与利培酮对首发精神分裂症患者认知功能及社会功能的影响(1)
[摘要] 目的 评价阿立哌唑与利培酮对首发精神分裂症患者认知功能及社会功能的影响。 方法 选择我院2016年7月～2018年6月收治的精神分裂症患者60例为本次研究对象，按照随机数字表法分为对照组30例与观察组30例。对照组给予利培酮治疗，观察组给予阿立哌唑治疗，对比两组患者认知功能及社会功能改善情况。 结果 PANSS情况：治疗前两组患者的PANSS评分比较，差异无统计学意义(P>0.05)，第12周时观察组优于对照组，差异存在统计学意义(P<0.05);第12周与治疗前比较，观察组组内评分存在统计学意义(P<0.05);MCCB情况：治疗前两组患者的TMTA、SC、AN、NAB-Mazes数据比较，差异无统计学意义(P>0.05)，第12周时除NAB-Mazes外其余因子观察组优于对照组，差异有统计学意义(P<0.05);PSP情况：治疗前两组患者的PSP评分比较无统计学意义(P>0.05)，第12周时两组患者PSP评分比较，差异无统计学意义(P>0.05);第12周与治疗前比较，两组组内评分均存在统计学意义(P<0.05)。 结论 阿立哌唑与利培酮用于治疗精神分裂症患者均能有效改善患者的社会功能，但阿立哌唑能够显著改善患者阴性症状与认知功能，值得临床应用与推广。
[关键词] 阿立哌唑;利培酮;精神分裂症;认知功能;社会功能
[中图分类号] R749.3 [文獻标识码] A [文章编号] 1673-9701(2019)14-0023-04
[Abstract] Objective To evaluate the effects of aripiprazole and risperidone on cognitive function and social function in patients with first-episode schizophrenia. Methods Sixty patients with schizophrenia admitted to our hospital from July 2016 to June 2018 were enrolled in this study. According to the random number table method， 30 patients were divided into the control group and 30 patients were divided into the observation group. The control group was treated with risperidone， and the observation group was treated with aripiprazole. The cognitive function and social function improvement of the two groups were compared. Results PANSS： There was no significant difference in PANSS score between the two groups before treatment(P>0.05). At 12 weeks， the observation group was superior to the control group， and the difference was statistically significant(P<0.05); At week 12， the scores of the observation group were statistically different from those before treatment(P<0.05). MCCB： There were no significant differences in TMTA， SC， AN， and NAB-Mazes between the two groups before treatment(P>0.05). At the 12th week， the other factors except NAB-Mazes were better in the observation group than in the control group(P<0.05). PSP： There was no significant difference in PSP score between the two groups before treatment(P>0.05). There was no significant difference in PSP score between the two groups at 12 weeks(P>0.05). At week 12， the scores of both groups were statistically different from those before treatment(P<0.05). Conclusion Both aripiprazole and risperidone can effectively improve the social function of patients with schizophrenia， but aripiprazole can significantly improve the negative symptoms and cognitive function of patients， which is worthy of clinical application and promotion., http://www.100md.com(刘会国)
[关键词] 阿立哌唑;利培酮;精神分裂症;认知功能;社会功能
[中图分类号] R749.3 [文獻标识码] A [文章编号] 1673-9701(2019)14-0023-04
[Abstract] Objective To evaluate the effects of aripiprazole and risperidone on cognitive function and social function in patients with first-episode schizophrenia. Methods Sixty patients with schizophrenia admitted to our hospital from July 2016 to June 2018 were enrolled in this study. According to the random number table method， 30 patients were divided into the control group and 30 patients were divided into the observation group. The control group was treated with risperidone， and the observation group was treated with aripiprazole. The cognitive function and social function improvement of the two groups were compared. Results PANSS： There was no significant difference in PANSS score between the two groups before treatment(P>0.05). At 12 weeks， the observation group was superior to the control group， and the difference was statistically significant(P<0.05); At week 12， the scores of the observation group were statistically different from those before treatment(P<0.05). MCCB： There were no significant differences in TMTA， SC， AN， and NAB-Mazes between the two groups before treatment(P>0.05). At the 12th week， the other factors except NAB-Mazes were better in the observation group than in the control group(P<0.05). PSP： There was no significant difference in PSP score between the two groups before treatment(P>0.05). There was no significant difference in PSP score between the two groups at 12 weeks(P>0.05). At week 12， the scores of both groups were statistically different from those before treatment(P<0.05). Conclusion Both aripiprazole and risperidone can effectively improve the social function of patients with schizophrenia， but aripiprazole can significantly improve the negative symptoms and cognitive function of patients， which is worthy of clinical application and promotion., http://www.100md.com(刘会国)